2096 — Simcere Pharmaceutical Balance Sheet
0.000.00%
- HK$21.51bn
- HK$20.73bn
- CNY6.64bn
- 77
- 28
- 97
- 79
Annual balance sheet for Simcere Pharmaceutical, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 3,274 | 2,183 | 2,623 | 2,018 | 1,943 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 1,915 | 2,436 | 2,379 | 2,695 | 2,704 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 6,467 | 4,980 | 5,458 | 5,639 | 5,466 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 2,128 | 1,931 | 2,139 | 2,170 | 2,270 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 10,943 | 10,161 | 10,789 | 10,854 | 11,510 |
Accounts Payable | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 3,497 | 3,064 | 2,967 | 2,686 | 2,727 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 5,642 | 3,724 | 3,657 | 3,631 | 4,442 |
Common Stock | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 5,302 | 6,437 | 7,132 | 7,223 | 7,068 |
Total Liabilities & Shareholders' Equity | 10,943 | 10,161 | 10,789 | 10,854 | 11,510 |
Total Common Shares Outstanding |